Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06783335 · ClinicalTrials.gov registry record
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
A clinical trial of Heart Failure and Heart Failure NYHA Class III, sponsored by Endotronix.
- Recruiting
- Registry status
- 2,150
- Enrollment target
- 1
- Study location
NCT06783335: Recruiting study of Heart Failure and Heart Failure NYHA Class III, sponsored by Endotronix.
NCT06783335 is a study of Heart Failure and Heart Failure NYHA Class III that is actively recruiting participants, run by Endotronix. The registered enrollment target is 2,150 participants, roughly in line with the 2,044-participant average among 397 other Heart Failure trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06783335, a study of Heart Failure and Heart Failure NYHA Class III, is actively recruiting participants, sponsored by Endotronix.
- RECRUITING
- Registry status
- 2,150 participants
- Enrollment target
- 1
- Study location
Study Summary
This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure. The study will track patients for two years to see if those using the Cordella system have fewer deaths and hospitalizations related to heart failure.
Primary Outcome
* Description: The cumulative number of all-cause deaths and heart failure hospitalizations * Time Frame: 2 years after study entry (time zero) * Statistical Analysis Plan: The primary analysis will use an Andersen-Gill recurrent event model to account for multiple hospitalizations within individuals * Primary outcome will be assessed in the overall population
Conditions Studied
Interventions
- DEVICE Cordella PA Sensor System
- DRUG Standard of Care Pharmacologic Therapy
Study Locations (1)
Illinois
- Endotronix - Naperville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,150 participants |
| Start Date | 2025-02-07 |
| Est. Completion | 2030-12-31 |
What NCT06783335 shows while recruiting
NCT06783335 is an observational study that tracks outcomes without assigning an intervention. Its 2,150 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 2,044-participant average among 397 other Heart Failure trials with a reported enrollment target.
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Cordella PA Sensor System is the first listed.
NCT06783335 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06783335 about?
NCT06783335 is a clinical study titled "Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure". This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure. The study will track patients for two years to see if those using the Cordella system have fewer deaths and hospi...
What is the current status of trial NCT06783335?
This trial is currently recruiting. The enrollment target is 2,150 participants. The study started on 2025-02-07. Estimated completion is 2030-12-31.
What conditions does trial NCT06783335 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure NYHA Class III.
What interventions are being tested in trial NCT06783335?
The interventions under investigation include: Cordella PA Sensor System (DEVICE), Standard of Care Pharmacologic Therapy (DRUG).
Who is sponsoring clinical trial NCT06783335?
This trial is sponsored by Endotronix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06783335 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06783335's enrollment target sits among peer trials
2,150 42nd of 397 higher than 356 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05805709 · 2,145 participants · NA
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
- NCT05742178 · 2,160 participants · NA
NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
- NCT03488693 · 2,140 participants · Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI